EQS-News: Epigenomics AG: Pareto and Warburg publish analyst research reports
Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.
- Berlin (Germany), September 5, 2023 - Epigenomics AG (Frankfurt General Standard: ECX1; the "Company") announces that the research reports recently published by Pareto Securities AS and Warburg Research GmbH issue buy recommendations for Epigenomics AG's share.
- Both analysts consider the sale of substantial assets to New Day Diagnostics LLC as a chance to realize the potential and value of Epigenomics' blood-based colorectal cancer test Epi proColon “Next-Gen”.
- With the shift from "Hold" to "Buy", Warburg even indicates that they consider the sale of significant assets likely to be more advantageous for shareholders than a further independent development.
- Pareto and Warburg set the price target at EUR 3.15 and EUR 3.30, respectively, subject to approval by Epigenomics AG's shareholders at the Extraordinary General Shareholders' Meeting on September 11, 2023, in Berlin.